Related Experiment Videos
Vigabatrin in pediatric epilepsy--an open study
Insights
Vigabatrin effectively reduced seizure frequency in children with severe epilepsy, with over half experiencing significant improvement. While some seizures recurred, they were less frequent, and the drug was generally well-tolerated.
Area of Science:
- Pediatric Neurology
- Clinical Pharmacology
- Epileptology
Background:
- Limited data exists on vigabatrin's long-term efficacy and safety in pediatric epilepsy.
- Adult studies confirm vigabatrin's antiepileptic effects.
Purpose of the Study:
- To evaluate the long-term effect and safety of vigabatrin as an add-on therapy in children with severe epilepsy.
- To assess the dose-ranging effects of vigabatrin in this population.
Main Methods:
- An open-label, add-on, dose-ranging study.
- Enrolled children with various epilepsy types, including partial epilepsy, generalized epilepsy, and Lennox-Gastaut syndrome.
- Monitored seizure frequency, adverse events, and physiologic effects.
Main Results:
- 54% of pediatric patients achieved >50% reduction in seizure frequency; 4 became seizure-free.
- Significant seizure reduction observed across the patient cohort, with recurrence at lower frequencies.
- 39% of patients reported adverse events; no significant impact on growth or physical examination.
Conclusions:
- Vigabatrin demonstrates significant long-term efficacy in reducing seizure frequency in children with severe epilepsy.
- The drug is generally well-tolerated in pediatric patients, with manageable adverse events.
- Further investigation into specific epilepsy syndromes may be warranted.
Abstract:
The antiepileptic effect of vigabatrin in adults has been demonstrated in a number of controlled studies. In children, the effect of vigabatrin has been investigated only to a limited extent. In order to assess the long-term effect and safety of vigabatrin in patients with severe epilepsy, an open, add-on, dose-ranging study was initiated. To date, 27 children with partial epilepsy, two with generalized epilepsy, two with Lennox-Gastaut syndrome, and one with nonclassifiable epilepsy have been enrolled in the trial. Fifty-four percent of patients have experienced a greater than 50% reduction in seizure frequency, and four patients have become seizure free. A significant reduction in seizures was noted across the patient population, although patients who were recorded as seizure free at 3 and 6 months did suffer some recurrence of seizures. However, when seizures recurred, they did so at much lower frequency than recorded at the start of the study. Thirteen patients (39%) reported adverse events attributable to vigabatrin; one was immediately withdrawn from the study, and six had their vigabatrin dose reduced. No physiologic effects were noted on normal growth or clinical physical examination.